{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:52:20Z","timestamp":1791903140717,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd015381","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000}}],"reference-count":86,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015381.pub2","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:04:37Z","timestamp":1761663877000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molnupiravir for treating COVID-19"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-3566","authenticated-orcid":false,"given":"Gayle S","family":"Tatz","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine; University of Cape Town; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor A","family":"Ochodo","sequence":"additional","affiliation":[{"name":"Centre for Global Health Research; Kenya Medical Research Institute; Kisumu Kenya"},{"name":"Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilly","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy J","family":"Owino","sequence":"additional","affiliation":[{"name":"Centre for Global Health Research; Kenya Medical Research Institute; Kisumu Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Nyagol","sequence":"additional","affiliation":[{"name":"Centre for Global Health Research; Kenya Medical Research Institute; Kisumu Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Rupali","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases; Christian Medical College Vellore; Tamil Nadu India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McCaul","sequence":"additional","affiliation":[{"name":"Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kredo","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"},{"name":"Divisions of Epidemiology and Biostatistics and Clinical Pharmacology; Faculty of Medicine and Health Sciences, University of Stellenbosch; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine; University of Cape Town; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"10242","key":"10.1002\/14651858.CD015381.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0140-6736(20)31142-9","article-title":"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis","volume":"395","author":"Chu","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0002|cit2","unstructured":"World Health Organization WHO updates its treatment guidelines to include molnupiravir. 3 March 2022. News release who.int\/news\/item\/03-03-2022-molnupiravir"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0003|cit3","unstructured":"World Health Organization Coronavirus disease (Covid-19) situation dashboard https:\/\/data.who.int\/dashboards\/covid19"},{"issue":"9","key":"10.1002\/14651858.CD015381.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD015381.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"e2228008","DOI":"10.1001\/jamanetworkopen.2022.28008","article-title":"Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis","volume":"5","author":"Wu","year":"2022","journal-title":"JAMA Network Open"},{"issue":"13","key":"10.1002\/14651858.CD015381.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316.","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD015381.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"50","key":"10.1002\/14651858.CD015381.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2101147","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101147","article-title":"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway","volume":"26","author":"Brandal","year":"2021","journal-title":"Euro Surveillance"},{"issue":"5152","key":"10.1002\/14651858.CD015381.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.15585\/mmwr.mm705152e3","article-title":"Investigation of a SARS-CoV-2 B.1.1.529 (omicron) variant cluster - Nebraska, November-December 2021","volume":"70","author":"Jansen","year":"2021","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1002\/14651858.CD015381.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/M20-6976","article-title":"The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review","volume":"174","author":"Oran","year":"2021","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015381.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"Journal of Medical Virology"},{"issue":"1","key":"10.1002\/14651858.CD015381.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13054-020-02902-w","article-title":"Clinical determinants for fatality of 44,672 patients with COVID-19","volume":"24","author":"Deng","year":"2020","journal-title":"Critical Care"},{"issue":"10223","key":"10.1002\/14651858.CD015381.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"7821","key":"10.1002\/14651858.CD015381.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0015|cit15","unstructured":"World Health Organization COVID-19 vaccination, World data (last updated 2024) https:\/\/data.who.int\/dashboards\/covid19\/vaccines?n=c (accessed 20 October 2025)"},{"issue":"5","key":"10.1002\/14651858.CD015381.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/tropicalmed7050081","article-title":"Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: a systematic review","volume":"7","author":"Gopinath","year":"2022","journal-title":"Tropical Medicine and Infectious Disease"},{"issue":"23","key":"10.1002\/14651858.CD015381.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"855496","DOI":"10.3389\/fimmu.2022.855496","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"13","author":"Tian","year":"2022","journal-title":"Frontiers Immunology"},{"issue":"11","key":"10.1002\/14651858.CD015381.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/antibiotics10111294","article-title":"Molnupiravir \u2013 a novel oral anti-SARS-CoV-2 agent","volume":"10","author":"Lee","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"10.1002\/14651858.CD015381.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"102396","DOI":"10.1016\/j.dsx.2022.102396","article-title":"An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes and Metabolic Syndrome"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0022|cit22","unstructured":"World Health Organization Therapeutics and COVID-19: living guideline. WHO\/2019-nCoV\/therapeutics\/2022.3. Updated 22 April 2022 Available at https:\/\/www.who.int\/publications\/i\/item\/B09540"},{"issue":"6","key":"10.1002\/14651858.CD015381.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"102329","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID\u201319: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"1","key":"10.1002\/14651858.CD015381.pub2-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014962.pub2","article-title":"Remdesivir for the treatment of COVID-19","author":"Grundeis","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015381.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013825.pub2","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD015381.pub2-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015395","article-title":"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19","author":"Reis","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1002\/14651858.CD015381.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for early COVID-19: a critical need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"10.1002\/14651858.CD015381.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.2020.16747","article-title":"Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic","volume":"324","author":"Prescott","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD015381.pub2-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015017.pub3","article-title":"Ivermectin for preventing and treating COVID-19","author":"Popp","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013587.pub2","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19","author":"Singh","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD015381.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015025","article-title":"Antibiotics for the treatment of COVID-19","author":"Popp","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD015381.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"Journal of Virology"},{"issue":"9","key":"10.1002\/14651858.CD015381.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nature Structural & Molecular Biology"},{"issue":"3","key":"10.1002\/14651858.CD015381.pub2-BIB0034|cit34","first-page":"166","article-title":"SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"71","author":"Li","year":"2022","journal-title":"Cell Research"},{"issue":"9","key":"10.1002\/14651858.CD015381.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nature Structural & Molecular Biology"},{"issue":"7987","key":"10.1002\/14651858.CD015381.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1002\/14651858.CD015381.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"e3002214","DOI":"10.1371\/journal.pbio.3002214","article-title":"Evolutionary safety of lethal mutagenesis driven by antiviral treatment","volume":"21","author":"Lobinska","year":"2023","journal-title":"PLoS Biology"},{"issue":"108475","key":"10.1002\/14651858.CD015381.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.reprotox.2023.108475","article-title":"An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations","volume":"121","author":"Marikawa","year":"2023","journal-title":"Reproductive Toxicology"},{"issue":"1","key":"10.1002\/14651858.CD015381.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxres\/tfae012","article-title":"Assessing the mitochondrial safety profile of the molnupiravir active metabolite, \u03b2-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model","volume":"13","author":"Kiy","year":"2024","journal-title":"Toxicology Research"},{"issue":"1","key":"10.1002\/14651858.CD015381.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/em.22471","article-title":"Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir","volume":"63","author":"Waters","year":"2022","journal-title":"Environmental and Molecular Mutagenesis"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0041|cit41","unstructured":"World Health Organization WHO Technical Advisory Group on Virus Evolution (TAG-VE) Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: NB.1.8.1 https:\/\/www.who.int\/publications\/m\/item\/risk-evaluation-for-sars-cov-2-variant-under-monitoring-nb.1.8.1"},{"issue":"1","key":"10.1002\/14651858.CD015381.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-021-00592-6","article-title":"SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"783982","DOI":"10.3389\/fmed.2021.783982","article-title":"Systematic review and meta-analysis of COVID-19 vaccination acceptance","volume":"8","author":"Norhayati","year":"2022","journal-title":"Frontiers in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015381.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jac\/dkad132","article-title":"Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"78","author":"Malin","year":"2023","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"11","key":"10.1002\/14651858.CD015381.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"e31508","DOI":"10.7759\/cureus.31508","article-title":"Efficacy and safety of molnupiravir in mild COVID-19 patients in India","volume":"14","author":"Sinha","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"10.1002\/14651858.CD015381.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015381","article-title":"Molnupiravir for treating COVID-19","author":"Ochodo","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015381.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0048|cit48","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0050|cit50","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"4","key":"10.1002\/14651858.CD015381.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ajic.2021.10.039","article-title":"Clinical characteristics and symptom duration among outpatients with COVID-19","volume":"50","author":"Lane","year":"2022","journal-title":"American Journal of Infection Control"},{"issue":"8","key":"10.1002\/14651858.CD015381.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/j.medine.2020.06.014","article-title":"Early mortality risk stratification after SARS-CoV-2 infection","volume":"45","author":"Lundon","year":"2021","journal-title":"Medicina Intensiva (English Edition)"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0053|cit53","unstructured":"Good Clinical Practice (GCP) E6 (R3) https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0054|cit54","unstructured":"Covidence systematic review software Veritas Health Innovation 2023"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0056|cit56","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0057|cit57","unstructured":"Sambunjak D Cumpston M Watts C Module 6: Analysing the data. In: Cochrane interactive learning: conducting an intervention review. Cochrane, 2017 Available from training.cochrane.org\/interactivelearning\/module-6-analysing-data https:\/\/training.cochrane.org\/interactivelearning"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0058|cit58","unstructured":"Review Manger (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0059|cit59","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0060|cit60","unstructured":"World Bank Country and Lending Groups; county classification datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables \u2013 binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0062|cit62","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0063|cit63","unstructured":"A multi-center, Phase- III clinical trial of molnupiravir capsules trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/05\/033693"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0064|cit64","unstructured":"A Phase III clinical trial to understand the efficacy and safety of molnupiravir 800mg in the treatment of patients diagnosed with mild COVID-19 trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/06\/034130"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0065|cit65","unstructured":"A Phase II\/III Clinical Trial to understand the efficacy and safety of molnupiravir 800mg in the treatment of patients diagnosed with moderate COVID-19 trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/06\/034220"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0066|cit66","unstructured":"The safety of molnupiravir (EIDD-2801) and its effect on viral shedding of SARS-CoV-2 (END-COVID) clinicaltrials.gov\/study\/NCT04405739"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0067|cit67","unstructured":"Open multicenter study for assessment of efficacy and safety of molnupiravir in adult patients with COVID-19 clinicaltrials.gov\/study\/NCT05595824"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0068|cit68","unstructured":"Pharmacokinetics, safety and efficacy study of GP30341 (GEROPHARM, Russia) clinicaltrials.gov\/study\/NCT05648799"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0069|cit69","unstructured":"This study is to evaluate benefit of adding Molnupiravir over standard treatments in mild COVID-19 subjects trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/06\/033938"},{"issue":"10373","key":"10.1002\/14651858.CD015381.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD015381.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD015381.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.7326\/m22-0729","article-title":"Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial","volume":"175","author":"Johnson","year":"2022","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Tippabhotla SK Lahiri S Rama Raju D Kandi C Naga Prasad V Efficacy and safety of molnupiravir for the treatment of non-hospitalized adults with mild COVID-19: a randomized, open-label, parallel-group Phase 3 trial Lancet [preprint] 2022 10.2139\/ssrn.4042673","DOI":"10.2139\/ssrn.4042673"},{"issue":"9","key":"10.1002\/14651858.CD015381.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S1473-3099(25)00093-3","article-title":"Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"25","author":"Abani","year":"2025","journal-title":"Lancet Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015381.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/jac\/dkab318","article-title":"Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study","volume":"76","author":"Khoo","year":"2021","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s1473-3099(22)00644-2","article-title":"Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"23","author":"Khoo","year":"2023","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015381.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"939573","DOI":"10.3389\/fphar.2022.939573","article-title":"Antiviral efficacy and safety of molnupiravir against Omicron variant infection: a randomized controlled clinical trial","volume":"13","author":"Zou","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"628","key":"10.1002\/14651858.CD015381.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Holman","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"EVIDoa2100044","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM Evidence"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"EVIDoa2100043","DOI":"10.1056\/EVIDoa2100043","article-title":"Phase 2\/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults","volume":"1","author":"Caraco","year":"2022","journal-title":"NEJM Evidence"},{"issue":"3","key":"10.1002\/14651858.CD015381.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/jac\/dkac440","article-title":"Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13\u200a694 patients with meta-analysis","volume":"78","author":"Lawrence","year":"2023","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD015381.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/MJT.0000000000001541","article-title":"Molnupiravir for the treatment of coronavirus disease 2019: a systematic review with meta-analysis of 12,451 patients","volume":"31","author":"Beran","year":"2024","journal-title":"American Journal of Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD015381.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"e28621","DOI":"10.1002\/jmv.28621","article-title":"Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: a systematic review and meta-analysis of randomized control trials","volume":"95","author":"Huang","year":"2023","journal-title":"Journal of Medical Virology"},{"issue":"9","key":"10.1002\/14651858.CD015381.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/jac\/dkad216","article-title":"Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34\u200a570 patients","volume":"78","author":"Sun","year":"2023","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD015381.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/apm.13373","article-title":"Virology and safety profile of molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis","volume":"132","author":"Sukaina","year":"2024","journal-title":"APMIS"},{"issue":"2","key":"10.1002\/14651858.CD015381.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"106870","DOI":"10.1016\/j.ijantimicag.2023.106870","article-title":"Efficacy and safety of molnupiravir treatment for COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Tian","year":"2023","journal-title":"International Journal of Antimicrobial Agents"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:32:24Z","timestamp":1791901944000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015381.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":86,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015381.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}